Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Food and Drug Administration (FDA)
Biotech
Lilly glides out of Leqembi slipstream with FDA meeting request
If you thought that Eli Lilly's donanemab could ensure a smooth regulatory flight in the slipstream of Eisai and Biogen, the FDA has other ideas.
Annalee Armstrong
Apr 17, 2024 5:00am
Neumora schizophrenia drug on FDA hold over rabbit convulsions
Apr 15, 2024 9:00am
ProJenX ALS drug gets back on the map after partial FDA hold
Mar 29, 2024 10:44am
Regeneron seeks clarity on confirmatory trials after FDA hurdle
Mar 29, 2024 5:00am
GAO: FDA should audit hiring efforts to boost worker retention
Mar 27, 2024 4:15pm
FDA blocks approval of Regeneron's blood cancer drug
Mar 25, 2024 9:25pm